

**AUDITORS' REPORT**  
*ON*  
**Utilization of IPO Proceeds**

We have audited the annexed Statement of Initial Public Offering (IPO) Proceeds Utilization of Silva Pharmaceuticals Limited for the month ended 31 December 2021 as per required by Bangladesh Securities and Exchange and Commission (BSEC) under Section 2CC of the Securities and Exchange Ordinance 1969.

**Management's Responsibility for the IPO proceeds Utilization**

Management is responsible for the preparation and fair presentation of these IPO proceeds utilization statement in accordance with Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 2, 3, 5 & 6 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated 28 June 2018 and other applicable laws and regulations.

**Auditor's Responsibility**

Our responsibility is to express an independent opinion on these Initial Public Offering (IPO) proceeds utilization statement based on our audit. We conducted our audit in accordance with International Standards on Auditing (ISA), Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 2, 3, 5 & 6 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated 28 June, 2018 and other applicable laws and regulations.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

**Opinion**

In our Opinion, the Statement of Initial Public Offering (IPO) Proceeds Utilization, prepared in accordance with Bangladesh Securities and Exchange Commission Rules 1987 and Condition laid down in clause 2, 3, 5 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated 28 June, 2018 and other applicable laws and regulations, gives a true and fair view of the statement for the month 31 December 2021.

**As per TOR, we draw attention to the following matter:**

1. During the month of December, 2021 no expenses has been incurred in respect of Civil Construction. However, the company has utilized accumulative amount of Tk. 60,532,650 up to 31 December 2021 which was 104.26% of the amount specified in the prospectus and thereafter revised utilization plan for the purpose of Civil Construction. As such, approval was a pre-requisite from the respected shareholders and concerned regulatory authority for the excess utilized amount of Tk. 2,474,124.

2. During the month of December, 2021 no expenses has been incurred in respect of Purchase New Machinery and Equipment's. However, the company has utilized accumulative amount of Tk. 32,585,847 which was 26.60% up to 31 December 2021 in respect of Purchase of Machinery and Equipment's.
3. The Company has utilized Tk. 99,000,000 which was 100% of the budgeted amount up to 31 December 2021 for the purpose of loan repayment as specified in the prospectus.
4. The Company has utilized Tk. 20,441,474 which was 100% of the budgeted amount up to 31 December for the purpose of IPO expenses as specified in the prospectus and thereafter revised utilization plan.

**We also state that:**

- a) IPO proceeds have been utilized for the purposes as specified in the prospectus and thereafter revised utilization plan except the above said issues no.1 of the Company;
- b) IPO proceeds have been utilized in so far line with the conditions of the BSEC's consent letter for the IPO except the above said issues no. 1.
- c) The time frame for completion of the utilization of IPO proceeds was revised and will be completed within the time frame as specified in the resolution of 19<sup>th</sup> Annual General Meeting (AGM).
- d) Utilization of IPO proceeds is accurate for the purpose of the company as mentioned in the prospectus and 18<sup>th</sup> AGM of the Company.
- e) Audit statement has been made on verification of all necessary documents/papers/vouchers in support of utilization of IPO proceeds making reconciliation with bank statements.

Dhaka, Bangladesh  
Dated: 10 January 2022

  
**Mohan Adhikari, FCA**  
Partner  
ICAB Enroll no: 1729  
**Pinaki & Company**  
Chartered Accountants



**Report on Utilization of IPO Proceeds**  
For the Month of December 2021

Name of the Company: **Silva Pharmaceuticals Limited**

Amount (BDT) of capital raised through IPO: **BDT 300,000,000**

Date of Closure of Subscription: **05 August 2018**

Proceeds Receiving Date: **30 October 2018**

Last date of full Utilization of IPO Fund as per Prospectus: **As stated in three line columns**

Name of the Company: **Silva Pharmaceuticals Limited**

Amount (BDT) of capital raised through IPO: **BDT 300,000,000**

Date of Closure of Subscription: **05 August 2018**

Proceeds Receiving Date: **30 October 2018**

Last date of full Utilization of IPO Fund as per Prospectus: **As stated in three line columns**

S.L	Purpose mentioned in the prospectus / 10th AGM	Time Line		Amount as per Prospectus	Amount as per Prospectus per 10th AGM	Amount as per Prospectus per 10th AGM	Status of Utilization						Remarks	
		As per Prospectus	As per 10th AGM				As per 10th AGM	As per 10th AGM	During the Month	Total Utilized Amount	Utilized %	Excess Utilized amount		Excess-utilized %
1	Civil Construction	09.04.2020	09.10.2020	31.12.2022	58,058,526	60,532,650	60,532,650	104.26	2,474,124	4.26	-	-	-	-
2	Machinery and Equipment	09.04.2020	09.10.2020	31.12.2022	122,500,000	32,585,847	32,585,847	26.60	-	-	69,914,153	73.40	-	-
3	Repayment of Bank Borrowing at prospectus	09.01.2019	N/A	N/A	99,000,000	99,000,000	99,000,000	100.00	-	-	-	-	-	-
4	IPO Expenses	N/A	N/A	N/A	20,441,474	20,441,474	20,441,474	100.00	-	-	-	-	-	-
<b>Total</b>						<b>212,559,971</b>	<b>212,559,971</b>	<b>70.85</b>	<b>2,474,124</b>	<b>0.82</b>	<b>89,914,153</b>	<b>29.97</b>		

Notes:

a) Annual application was received almost 25.76 Times.

b) IPO proceeds have been utilized for the purposes/benefits as specified in the prospectus and in line with the condition of the Commission's consent letter.

24,057,556

111,477,586

c) Interest on IPO Proceeds in BDT (from FDI & SND) -

d) Un-Utilized IPO Proceeds with interest income in BDT -



**Dr. Saira Khan**  
Managing Director



**Md. Abul Kasem**  
Chief Financial Officer



**Silvana Mirza**  
Chairman



**Md. Imrul Hossain**  
Company Secretary



**Mohan Adhikari, FCS**  
Partner

ICAB Enroll. No. 1729

**Pinaki & Company**  
Chartered Accountants

Dhaka, Bangladesh

Dated: 16 January 2022